Evidence map›Paper›PMID 28745332›Full record

SynthesisLeukemia2017

Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group.

O Al-Sawaf, S Robrecht, J Bahlo, A M Fink, P Cramer, J von Tresckow, C Maurer, M Bergmann, T Seiler, E Lange and 11 more

2 registry-linked trialsAbstract readMeta-Analysis
PubMed Publisher
In one paragraph

Synthesis in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00274989 phase2completednot on this map

Multicentre Phase II Trial of Bendamustine in Combination With Rituximab for Patients With Previously Untreated or Relapsed Chronic Lymphocytic Leukemia. CLL2M Protocol of the German CLL-Study Group (GCLLSG)

TypeinterventionalSponsorGerman CLL Study GroupRan2005 to 2011Enrolled195ConditionsChronic Lymphocytic LeukemiaArmsBendamustine, Rituximab
NCT00769522 phase3completednot on this map

Phase III Trial of Combined Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab (FCR) Versus Bendamustine and Rituximab (BR) in Patients With Previously Untreated Chronic Lymphocytic Leukaemia

TypeinterventionalSponsorGerman CLL Study GroupRan2008 to 2018Enrolled564ConditionsChronic Lymphocytic LeukemiaArmsRituximab, Bendamustine, Cyclophosphamide, Fludarabine
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. [Sex-specific differences of special tumor diseases].Innere Medizin (Heidelberg, Germany) · 2023
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

O Al-SawafDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
S RobrechtDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
J BahloDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
A M FinkDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
P CramerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
J von TresckowDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
C MaurerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
M BergmannDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Hospital Munich-Schwabing, Munich, Germany.
T SeilerMedical Department III, University Hospital of the Ludwig-Maximilians-University, Munich, Germany.
E LangeDepartment of Hematology and Oncology, Evangelisches Krankenhaus Hamm, Hamm, Germany.
M KnebaSecond Department of Medicine, University Hospital of Schleswig-Holstein, Kiel, Germany.
S StilgenbauerDepartment of Internal Medicine III, German CLL Study Group, University Hospital of Ulm, Ulm, Germany.
H DöhnerDepartment of Internal Medicine III, German CLL Study Group, University Hospital of Ulm, Ulm, Germany.
M G KiehlDepartment of Internal Medicine, Frankfurt (Oder) General Hospital, Frankfurt/Oder, Germany.
U JägerDivision of Hematology and Hemostaeology, Department of Internal Medicine I, Medical University Vienna, Vienna, Austria.
C M WendtnerDepartment of Hematology, Oncology, Immunology, Palliative Care, Infectious Diseases and Tropical Medicine, German CLL Study Group, Hospital Munich-Schwabing, Munich, Germany.
K FischerDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
V GoedeDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
M HallekDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
B EichhorstDepartment I of Internal Medicine and Center of Integrated Oncology Cologne-Bonn, German CLL Study Group, University Hospital, Cologne, Germany.
G HopfingerDepartment of Internal Medicine I, Bone Marrow Transplantation, Medical University of Vienna, Vienna, Austria.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

AdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsClinical Trials, Phase II as TopicClinical Trials, Phase III as TopicFemaleGender IdentityHumansImmunotherapyLeukemia, Lymphocytic, Chronic, B-CellMaleMiddle AgedTreatment Outcome

Identifiers

PMID28745332

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.